Cannabidiol in autism: Clinical pharmacology priorities for trial design
Open Access
- 29 November 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 357-359
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cannabidiol (CBD) Treatment for Severe Problem Behaviors in Autistic Boys: A Randomized Clinical TrialJournal of Autism and Developmental Disorders, 2025
- Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trialAsian Journal of Psychiatry, 2024
- Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label studyTranslational Psychiatry, 2022
- Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disordersNeuropsychopharmacology, 2020
- Parasitic pharmacology: A plausible mechanism of action for cannabidiolBritish Journal of Clinical Pharmacology, 2019
- Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking testBrazilian Journal of Psychiatry, 2019
- Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and EfficacyScientific Reports, 2019
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut SyndromeNew England Journal of Medicine, 2018
- Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic reviewDrug Metabolism Reviews, 2013
- Standardizing ADOS Scores for a Measure of Severity in Autism Spectrum DisordersJournal of Autism and Developmental Disorders, 2008